On March 11, 2014 the FDA approved Topiramate, marketed as Qudexy™ XR by Upsher-Smith Laboratories, for the treatment of partial-onset seizures (POS) or primary generalized tonic-clonic seizures in patients 10+ years of age. It is also approved as adjunctive therapy in patients 2+ years of age for the aforementioned seizures, and seizures associated with Lennox-Gastaut[…]
Topiramate Approved as Antiepileptic Drug
Anti-Migraine, Anti-Obesity Product, FDA Approved 2014 Tags: Annual MeetingepilepsyTopiramate Mar 14, 2014
Temsirolimus Combo Therapy Increases Cancer Remission
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, Immunosuppressant Tags: acute myeloid leukemiaAnnual Meetingcancer treatmentchemotherapy Jun 21, 2011
Over the past decade, pharmaceutical firms have been giving oncologists the choice to combine several drugs used in cancer treatment in order to battle even the most resistant of cancer cells. This move has been proven successful in some types of cancer, prompting pharmaceutical manufacturers to supply consistent, quality-controlled active pharmaceutical ingredients (API’s), such as[…]
Ramoplanin – protecting patients against CDAD attacks in hospitals
Antibiotic, Drug Research & Development API Tags: Annual Meetingantibiotic Jan 10, 2011
Ramoplanin is an antibiotic glycolipodepsipeptide drug that can be used as a treatment for patients suffering with Clostridium difficile infection (CDAD infection) of the gastrointestinal tract. This drug was approved by the US Food and Drug Administration (FDA); however, this drug is considered unstable in the blood, and it degrades to inactive parts. Therefore, Ramoplanin[…]
